Celgene Corporation Presents Data on Two Classes of Compounds From Its Inflammatory Disease, Cytokine Inhibitor Platform

Apr 26, 2001, 01:00 ET from Celgene Corporation

     Selcids(TM) and the JNK Inhibitors Demonstrate Potent and Selective
                           Anti-Inflammatory Effects
 
     PARIS, April 26 /PR Newswire Interactive Release/ -- Celgene Corporation
 (Nasdaq:   CELG) scientists and collaborators presented data today at the New
 Targets in Arthritis: Signal Transduction and Transcriptional Regulation
 meeting of the Institut Pasteur.  The researchers reported that Celgene's
 SelCIDs(TM) (Selective Cytokine Inhibitory Drugs) and novel JNK
 (c-Jun N-terminal Kinase) inhibitor have significant anti-inflammatory
 properties that may be beneficial to the treatment of immune and inflammatory
 diseases, including rheumatoid arthritis.
     Dr. David I. Stirling, Chief Scientific Officer of Celgene Corporation,
 presented results of studies evaluating the anti-inflammatory properties of
 the SelCIDs. The SelCIDs are potent inhibitors of phosphodiesterase type
 4 (PDE4), an enzyme whose selective inhibition has been shown to be effective
 in animal models of asthma and inflammation. Selective PDE4 inhibitors have
 also been shown to potently inhibit tumor necrosis factor-alpha(TNF-alpha), a
 key inflammatory cytokine whose over-production is associated with a number of
 serious inflammatory diseases, including rheumatoid arthritis, asthma and
 inflammatory bowel disease.  PDE4 inhibitors, although shown to have potential
 therapeutic benefit in the treatment of asthma, have also been found to have
 undesirable biological activities including nausea and emesis.  Dr. Stirling
 reported on new SelCIDs that are potent and selective PDE4 inhibitors that
 demonstrated significant anti-inflammatory activity with minimal side effects.
 These SelCIDs were evaluated in ferret models of asthma and emesis in which
 they were found to be potent anti-inflammatory agents with minimal side
 effects at therapeutic dosing levels. The SelCIDs presented inhibit PDE4 and
 have TNF-alpha inhibitory effects.  Furthermore, they are superior in cellular
 activity to other PDE4 inhibitors currently in the clinic, but significantly,
 are without the emetic effects typically associated with PDE4 inhibitors.
     The first Celgene SelCID advanced into clinical development, CDC-801, has
 successfully completed two Phase I trials. It is presently being evaluated in
 a Phase II, double-blinded, placebo-controlled clinical trial in Crohn's
 disease. Celgene has also advanced one of its second-generation SelCIDs,
 CDC-998, into initial human safety testing in late 2000. CDC-998 is greater
 than 100-fold more potent than CDC-801 against PDE4. In the initial single
 dose Phase I trial, CDC-998 was well tolerated at the doses tested without any
 serious adverse effects. Plans for advancing CDC-998 into a multiple dosing
 trial are in place. CDC-998's selective PDE4 and TNF-alpha inhibition suggest
 that the drug candidate may have utility in treating a wide range of
 inflammatory diseases including respiratory, rheumatic and inflammatory
 diseases.
     Also at the Institut Pasteur conference, Dr. Alan Lewis, President of the
 Signal Research Division of Celgene, presented data on the pivotal role of
 mitogen-activated protein kinase (MAP kinase) cascades, including JNK, in
 inflammation and arthritis.  The data showed that JNK is a key regulator of
 physiologically important cytokines and growth factors including IL-2,
 TNF-alpha and VEGF.  Data presented on the small-molecule inhibitors
 discovered at Celgene confirmed the importance of this pathway in controlling
 immunoinflammatory events in animal models of arthritis as well as other
 inflammatory diseases.  Dr. Lewis also presented data showing that Celgene's
 novel JNK inhibitors selectively inhibit cytokine expression in primary human
 leukocytes and block T-cell activation and differentiation.  Celgene intends
 to file an Investigational New Drug application for a novel JNK inhibitor
 within the next year.
     In addition to the presentations given by Drs. Stirling and Lewis, Dr.
 Gary Firestein of the University of California at San Diego, presented data
 showing the important role of certain signal transduction pathways in
 rheumatoid arthritis.  He stated that a variety of transcription factors
 regulate protease and cytokine expression and are therefore likely to be key
 regulatory elements in rheumatoid arthritis. Specifically, he presented
 studies demonstrating that the JNK pathway plays a fundamental role in the
 pathogenic joint destruction that occurs in arthritis.  Dr. Firestein also
 gave an overview of the data he presented at the American College of
 Rheumatology conference in November 2000, which demonstrated that Celgene's
 novel small-molecule JNK inhibitor is a potentially important new treatment
 for rheumatoid arthritis.
 
     Celgene Corporation, headquartered in Warren, New Jersey, is an
 independent biopharmaceutical company engaged in the discovery, development
 and commercialization of small molecule drugs for cancer and immunological
 diseases.  Please feel free to visit the Company's website at
 http://www.celgene.com.
 
     This release contains certain forward-looking statements which involve
 known and unknown risks, delays, uncertainties and other factors not under the
 Company's control which may cause actual results, performance or achievements
 of the Company to be materially different from the results, performance or
 other expectations implied by these forward-looking statements.  These factors
 include results of current or pending research and development activities,
 actions by the FDA and other regulatory authorities, and those factors
 detailed in the Company's filings with the Securities and Exchange Commission
 such as 10K, 10Q and 8K reports.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X37694474
 
 

SOURCE Celgene Corporation
     Selcids(TM) and the JNK Inhibitors Demonstrate Potent and Selective
                           Anti-Inflammatory Effects
 
     PARIS, April 26 /PR Newswire Interactive Release/ -- Celgene Corporation
 (Nasdaq:   CELG) scientists and collaborators presented data today at the New
 Targets in Arthritis: Signal Transduction and Transcriptional Regulation
 meeting of the Institut Pasteur.  The researchers reported that Celgene's
 SelCIDs(TM) (Selective Cytokine Inhibitory Drugs) and novel JNK
 (c-Jun N-terminal Kinase) inhibitor have significant anti-inflammatory
 properties that may be beneficial to the treatment of immune and inflammatory
 diseases, including rheumatoid arthritis.
     Dr. David I. Stirling, Chief Scientific Officer of Celgene Corporation,
 presented results of studies evaluating the anti-inflammatory properties of
 the SelCIDs. The SelCIDs are potent inhibitors of phosphodiesterase type
 4 (PDE4), an enzyme whose selective inhibition has been shown to be effective
 in animal models of asthma and inflammation. Selective PDE4 inhibitors have
 also been shown to potently inhibit tumor necrosis factor-alpha(TNF-alpha), a
 key inflammatory cytokine whose over-production is associated with a number of
 serious inflammatory diseases, including rheumatoid arthritis, asthma and
 inflammatory bowel disease.  PDE4 inhibitors, although shown to have potential
 therapeutic benefit in the treatment of asthma, have also been found to have
 undesirable biological activities including nausea and emesis.  Dr. Stirling
 reported on new SelCIDs that are potent and selective PDE4 inhibitors that
 demonstrated significant anti-inflammatory activity with minimal side effects.
 These SelCIDs were evaluated in ferret models of asthma and emesis in which
 they were found to be potent anti-inflammatory agents with minimal side
 effects at therapeutic dosing levels. The SelCIDs presented inhibit PDE4 and
 have TNF-alpha inhibitory effects.  Furthermore, they are superior in cellular
 activity to other PDE4 inhibitors currently in the clinic, but significantly,
 are without the emetic effects typically associated with PDE4 inhibitors.
     The first Celgene SelCID advanced into clinical development, CDC-801, has
 successfully completed two Phase I trials. It is presently being evaluated in
 a Phase II, double-blinded, placebo-controlled clinical trial in Crohn's
 disease. Celgene has also advanced one of its second-generation SelCIDs,
 CDC-998, into initial human safety testing in late 2000. CDC-998 is greater
 than 100-fold more potent than CDC-801 against PDE4. In the initial single
 dose Phase I trial, CDC-998 was well tolerated at the doses tested without any
 serious adverse effects. Plans for advancing CDC-998 into a multiple dosing
 trial are in place. CDC-998's selective PDE4 and TNF-alpha inhibition suggest
 that the drug candidate may have utility in treating a wide range of
 inflammatory diseases including respiratory, rheumatic and inflammatory
 diseases.
     Also at the Institut Pasteur conference, Dr. Alan Lewis, President of the
 Signal Research Division of Celgene, presented data on the pivotal role of
 mitogen-activated protein kinase (MAP kinase) cascades, including JNK, in
 inflammation and arthritis.  The data showed that JNK is a key regulator of
 physiologically important cytokines and growth factors including IL-2,
 TNF-alpha and VEGF.  Data presented on the small-molecule inhibitors
 discovered at Celgene confirmed the importance of this pathway in controlling
 immunoinflammatory events in animal models of arthritis as well as other
 inflammatory diseases.  Dr. Lewis also presented data showing that Celgene's
 novel JNK inhibitors selectively inhibit cytokine expression in primary human
 leukocytes and block T-cell activation and differentiation.  Celgene intends
 to file an Investigational New Drug application for a novel JNK inhibitor
 within the next year.
     In addition to the presentations given by Drs. Stirling and Lewis, Dr.
 Gary Firestein of the University of California at San Diego, presented data
 showing the important role of certain signal transduction pathways in
 rheumatoid arthritis.  He stated that a variety of transcription factors
 regulate protease and cytokine expression and are therefore likely to be key
 regulatory elements in rheumatoid arthritis. Specifically, he presented
 studies demonstrating that the JNK pathway plays a fundamental role in the
 pathogenic joint destruction that occurs in arthritis.  Dr. Firestein also
 gave an overview of the data he presented at the American College of
 Rheumatology conference in November 2000, which demonstrated that Celgene's
 novel small-molecule JNK inhibitor is a potentially important new treatment
 for rheumatoid arthritis.
 
     Celgene Corporation, headquartered in Warren, New Jersey, is an
 independent biopharmaceutical company engaged in the discovery, development
 and commercialization of small molecule drugs for cancer and immunological
 diseases.  Please feel free to visit the Company's website at
 http://www.celgene.com.
 
     This release contains certain forward-looking statements which involve
 known and unknown risks, delays, uncertainties and other factors not under the
 Company's control which may cause actual results, performance or achievements
 of the Company to be materially different from the results, performance or
 other expectations implied by these forward-looking statements.  These factors
 include results of current or pending research and development activities,
 actions by the FDA and other regulatory authorities, and those factors
 detailed in the Company's filings with the Securities and Exchange Commission
 such as 10K, 10Q and 8K reports.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X37694474
 
 SOURCE  Celgene Corporation